How RFK Jr. could strip vaccine makers of protections at HHS

Taking stock of the drug industry, from the lab to the medicine chest

November 18, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Anna Yeo/STAT STAT+ | How RFK Jr. could strip legal protections from vaccine makers as HHS Secretary RFK Jr., a longtime critic of legal protections for vaccine producers, could use a bureaucratic maneuver to upend decades of settled policy By Rachel Cohrs Zhang STAT+ | Syndax wins U.S. approval for leukemia treatment This genetic type of leukemia is present in approximately 10% of cases, and leads to high relapse rates and survival of less than a year By Adam Feuerstein STAT+ | Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular therapy. By Elizabeth Cooney Dr. Edwin P. Ewing, Jr./CDC STAT+ | Regenxbio says gene therapy strengthened boys with Duchenne muscular dystrophy Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue accelerated approval. By Adam Feuerstein STAT+ | AHA 2024: First, a call for prevention. Then a spotlight on obesity drugs As cardiovascular disease rises, the AHA examines studies of tools old, new, and recycled. By Elizabeth Cooney

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser